










































Gene therapy for lung inflammatory diseases: not so far away?
Citation for published version:
Sallenave, JM, Porteous, DJ & Haslett, C 1997, 'Gene therapy for lung inflammatory diseases: not so far
away?' Thorax, vol. 52, no. 8, pp. 742-4.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




available via europepmc open access link
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
742 Thorax 1997;52:742–744
Science matters Series editors G J Laurent and D F Rogers
Gene therapy for lung inflammatory diseases:
not so far away?
Jean-Michel Sallenave, David J Porteous, Christopher Haslett
Abstract promising results.1–3 The advances made in
these areas have prompted interest in the roleThe lung is a readily accessible target
organ for gene therapy. To date, thera- of gene therapy as a means of positively in-
fluencing more complex pulmonary disorderspeutic gene delivery has largely focused on
introducing functional, corrective genes such as inflammatory lung diseases which might
appear at first sight to be less amenable toin lung diseases arising from single gene
defects such as cystic fibrosis. More re- genetic intervention. We shall confine our dis-
cussion to the potential application of genecently interest has centred on gene therapy
as a potential therapeutic tool in mod- therapy in inflammatory lung diseases (as an
example of complex disease processes in theulating complex pathological processes
such as pulmonary inflammation. Genetic lung); however, it should be noted that far-
reaching and promising advances have beenmodification of critical components of the
inflammatory process may be beneficial – made in applying gene therapy to, for example,
lung tumours and HIV infection.for example, overexpressing anti-elastase
genes may circumvent elastase mediated
lung damage in emphysema. With the de-
velopment of improved viral and liposome Scientific basis
vectors and the evolution of effective ad-       
juvant immunosuppression to obviate host  ?
immune responses – for example, using To date over 100 clinical trials of gene therapy
selective cytokines and blockers of T cell for cancer have been conducted and reported,
surface activation – the potential exists to as well as 12 trials assessing gene therapy for
target therapeutic doses of transgene to HIV and a further 21 for single gene defects
deficient or dysregulated cells. Further- (mostly cystic fibrosis and a1AT deficiency).
more, increased understanding of tissue- However, as far as we are aware, no trials have
specific promoter regions and of mech- assessed gene therapy for inflammatory lung
anisms controlling regulation of gene diseases such as chronic obstructive pulmonary
expression offer the potential for close con- disease (COPD), adult respiratory distress syn-
trol of therapeutic gene expression within drome (ARDS), and asthma.
the lung. Continuing refinements in these The prevailing hypothesis is that inflam-
technologies will provide new therapeutic matory conditions such as COPD and ARDS
strategies in inflammatory lung disease. arise from an imbalance between potentially
Rayne Laboratory, (Thorax 1997;52:742–744) injurious inflammatory agents (for example,Department of
neutrophil-derived elastase and reactive oxygenMedicine,
Keywords: gene therapy, adenovirus, liposomes, elas-University of species) and tissue protective mechanisms.
tase, elastase inhibitors.Edinburgh Much is now known about mechanisms ofMedical School,
tissue defence and cytoprotection in these con-Teviot Place,
Edinburgh EH8 9AG, ditions, leading to our interest in the mani-
UK pulation of these processes by gene therapy.The aim of somatic gene therapy is to replace,J-M Sallenave
modify, or suppress the genes considered re-C Haslett
sponsible for a given disease process. The lung
MRC Human Genetics is a particularly attractive organ for gene ther-      Unit,
apy because of its accessibility via the airways   ?Western General
Hospital, or the vasculature. The main technical hurdle to be overcome is
Crewe Road, Cystic fibrosis and a1-antitrypsin (a1AT) de- delivering the appropriate gene to the nucleusEdinburgh EH2 2XU,
ficiency are the two most common fatal single using a vector associated with minimal toxicityUK
D J Porteous gene defects affecting the lung in the Western and maximal efficacy.
The armamentarium of vectors for gene de-world. The genetic abnormalities in these con-Correspondence to:
Dr J-M Sallenave. ditions have been well characterised and led to livery includes liposomes, viral vectors (retro-
virus, adenovirus, vaccinia, herpes virus, andReceived 14 October 1996 these diseases becoming the first logical targets
Returned to authors for lung-directed gene therapy. Indeed, several adeno-associated virus4), and molecular con-26 November 1996
Revised version received trials of specific gene replacement (using the jugates.4 In the context of the lung, liposomes
30 April 1997 adenovirus vector for gene carriage in the USA and adenoviruses are particularly attractive.Accepted for publication
9 May 1997 and liposome vectors in the UK) have shown Cationic liposomes, while causing little or no
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achieved by the use of conventional immuno-
suppressive drugs such as corticosteroids,
cyclosporin, or FK506 or, more specifically, by
using cytokines such as interleukin (IL)-128
which decreases neutralising IgA in the res-
piratory tract by switching off the CD4+ Th2
response and by blocking co-stimulatory re-
ceptors on antigen presenting cells and lym-
phocytes such as B7/CD28 and CD40/CD40
ligand, thus reducing lymphocyte activation.
Such approaches allow both sustained ex-
pression and safe repeated administration of
the transgene.9 10
Further attempts to reduce host inflam-
matory responses and to enhance cell specificity
and nuclear targeting are the focus of con-
siderable research, and removal of the major
hurdles toward effective, repeated gene therapy
are keenly anticipated.
Therapeutic potential
The process of pulmonary inflammation is
initiated by the stimulation of sequential
migration of inflammatory cells from the cir-
culation into the lung. Many pro-inflammatory
molecules are potential targets for gene therapy.
The influx of inflammatory cells could be pre-
vented by counteracting the effects of selected
cytokines and chemokines. For example, in
situations where the “early” cytokines IL-1
and tumour necrosis factor (TNF) have been
associated with adverse effects (such as in
sepsis), overexpression of IL-1 receptor an-
tagonist and soluble TNF receptor might be
beneficial. Chemokines such as IL-8, re-
sponsible for the influx of neutrophils in ARDS,
could be targeted using specific antisense DNA.























cells, endothelial cells, and epithelial cells could
Figure 1 Gene therapy at a lung inflammatory locus. The adult respiratory distress be downregulated.syndrome (ARDS) is characterised by both a local and systemic inflammation and is
Alternatively, overexpression of anti-in-triggered by a variety of stimuli, including bacterial endotoxin. Human neutrophil elastase
(HNE, Ν) is one enzyme released by the activated neutrophil which is believed to be flammatory cytokines such as IL-10 could be
involved in the pathology by destroying both the interstitium and the endothelium. beneficial in the resolution of inflammation.Protection against HNE could be provided by gene therapy using, for example, adenovirus
Indeed, recent in vivo work in rodents has(AD) and liposomes (LIP) to deliver genes for elastase inhibitors such as a1 proteinase
inhibitor, secretory leucocyte proteinase inhibitor, or elafin (ΕΝ). Both the airway shown that IL-10 can efficiently inhibit pul-
epithelium and the vasculature endothelium represent potential targets for gene therapy. monary inflammation by reducing both eos-
inophilia and neutrophilia, presumably, in the
latter, through the promotion of apoptosis.11
Intervention by modulating intracellular factorsinflammation when administered in vivo, are
in general poor gene transducers compared can also be envisaged. For example, the nuclear
factor NF-jB, which is known to be up-with adenoviruses. The latter have the opposite
characteristics in that gene transduction is regulated during inflammation and involved in
transcription of many inflammatory moleculesefficient (by virtue of mechanisms avoiding
lysosomal degradation and promoting transfer (for example, IL-1, IL-6, IL-8, VCAM-1), has
recently been targeted by the overexpression ofto the nucleus) but significant inflammation
and a specific immune response are induced in its inhibitor IjBa. However, the relative lack
of specificity of such nuclear factors must bevivo.
Addition of specific peptides (growth factors, carefully considered and may ultimately limit
their clinical application.hormones, receptor ligands, or monoclonal
antibodies) to liposome formulations can con- For the approaches discussed to be successful
in obviating lung inflammation, careful plan-fer cell-specific targeting.5 Furthermore, the
poor transducing capability of liposomes can ning of the timing and duration of gene therapy
will be vital. It will therefore be necessary tobe addressed by increasing nuclear tropism
using nuclear localisation signals. Reduction introduce mechanisms capable of “switching
on” and “switching off” therapeutic genes. Oneof the pro-inflammatory and immunogenic
properties of adenovirus vectors has been such mechanism attracting attention involves
the use of inducible promoters for expressionapproached mainly by deleting some or all of
the adenovirus genes6 7 and by manipulating of selected genes. Examples of such promoters
include the heat shock, tetracycline- andthe host immune response. The latter can be
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steroid-responsive promoters. Furthermore, ameliorating the specificity and durability of
expression, and in manipulating the host im-the use of lung-specific promoters such as sur-
factant protein C or Clara cell 10 kDa pro- mune response. At present liposomes and ad-
enoviruses (or a combination of both) are themoters will ensure tissue-specific expression of
therapeutic genes. preferred vectors for use in the lungs, but if
trials prove its safety then adeno-associatedWhile there are clearly several attractions
in aiming to attenuate the transmigration of virus could offer an attractive alternative by
virtue of its selective integration site in humaninflammatory cells into tissues, a more effective
and possibly safer strategy may be to inactivate chromosome 19, conferring stable and sus-
tainable expression.the potentially deleterious enzymes and reactive
oxygen species liberated by effector cells in
situ. Animal models of pulmonary inflamma- 1 Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS,
Mastrangeli A, Hay JG, et al. Administration of an adeno-tion have clearly implicated the overexpression virus containing the human CFTR cDNA to the res-
of elastase and reactive oxygen species in the piratory tract of individuals with cystic fibrosis. Nature
Genet 1994;8:42–51.development of lung injury suggesting that en- 2 Caplen NJ, Alton EWFW, Middleton PG, Dorin JR, Ste-
hanced production of elastase inhibitors or oxi- venson BJ, Gao X, et al. Liposome-mediated CFTR gene
transfer to the nasal epithelium of patients with cysticdant scavenger molecules (such as superoxide fibrosis. Nature Med 1995;1:3946.
dismutase) may have a significant protective 3 Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H,
Davidson H, Stevenson BJ, et al. Evidence for safety andeffect. Indeed, several elastase inhibitors such efficacy of DOTAP cationic liposome mediated CFTR
as a1-antitrypsin, secretory leucocyte proteinase gene transfer to the nasal epithelium of patients with cystic
fibrosis. Gene Therapy 1997;4:210–8.inhibitor (SLPI), and elafin have been ex- 4 Curiel DT, Pilewski JM, Abelda, SM. Gene therapy ap-
tensively characterised12 and a gene aug- proaches for inherited and acquired lung diseases. Am J
Respir Cell Mol Biol 1996;14:1–18.mentation approach might logically be 5 Miller N, Vile R. Targeted vectors for gene therapy. FASEB
expected to tip the inflammatory process in J 1995;9:190–9.
6 Bramson JL, Graham FL, Gauldie J. The use of adenoviralfavour of protection rather than excessive tissue vectors for gene therapy and gene transfer in vivo. Curr
injury (fig 1). Opin Biotechnol 1995;6:590–5.
7 Fisher KJ, Choi H, Burda J, Chen SJ, Wilson J. Recombinant
adenovirus deleted of all viral genes for gene therapy of
cystic fibrosis. Virology 1996;217:11–22.
8 Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 pre-Conclusion vents formation of blocking IgA antibodies to recombinant
Historically, emphasis in gene therapy has been adenovirus and allows repeated gene therapy to mouse
lung. Nature Med 1995;1:890–3.directed towards treatment of single gene de- 9 Kay MA, Holterman AX, Mense L, Gown A, Ochs, HD,
fects such as cystic fibrosis. We believe, how- Linsley PS, et al. Long term hepatic adenovirus-mediated
gene expression in mice following CTLA4Ig ad-ever, that targeted gene therapy may, in the ministration. Nature Genet 1995;11:191–7.
next few years, make a contribution to the 10 Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM.
Transient subversion of CD40 ligand function diminishestreatment options for lung diseases with multi- immune responses to adenovirus vectors in mouse liver
factorial aetiology such as COPD and ARDS. and lung tissues. J Virol 1996;70:6370–7.
11 Cox G. Interleukin-10 enhances resolution of pulmonaryKey factors in the pathogenesis of these con- inflammation in vivo by promoting apoptosis of neutro-
ditions have been identified (such as un- phils. Am J Physiol (Lung Cell Mol Physiol) 1996;271:
L566–71.regulated release of neutrophil elastase) and 12 Sallenave JM, Schulman J, Crossley J, Jordana M, Gauldie
have suggested which specific genes may be of J. Regulation of secretory leukocyte proteinase inhibitor
(SLPI) and elastase-specific inhibitor (ESI/Elafin) inmost therapeutic benefit. However, improve- human airway epithelial cells by cytokines and neutrophilic
ments require to be made in vector design, in enzymes. Am J Respir Cell Mol Biol 1994;11:733–41.
